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An Endogenous Inhibitor of Nitric Oxide Synthase
Regulates Endothelial Adhesiveness for Monocytes
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Jason R. Chan, BS, John P. Cooke, MD, PHD
Stanford, California
OBJECTIVES We sought to determine whether asymmetric dimethylarginine (ADMA) inhibits nitric oxide
(NO) elaboration in cultured human endothelial cells and whether this is associated with the
activation of oxidant-sensitive signaling mediating endothelial adhesiveness for monocytes.
BACKGROUND Endothelial NO elaboration is impaired in hypercholesterolemia and atherosclerosis, which
may be due to elevated concentrations of ADMA, an endogenous inhibitor of NO synthase.
METHODS Human umbilical vein endothelial cells (ECV 304) and human monocytoid cells (THP-1)
were studied in a functional binding assay. Nitric oxide and superoxide anion (O2
2) were
measured by chemiluminescence; ADMA by high pressure liquid chromatography; monocyte
chemotactic protein-1 (MCP-1) by ELISA and NF-kB by electromobility gel shift assay.
RESULTS Incubation of endothelial cells with ADMA (0.1 mM to 100 mM) inhibited NO formation,
which was reversed by coincubation with L-arginine (1 mM). The biologically inactive
stereoisomer symmetric dimethylarginine did not inhibit NO release. Asymmetric dimethy-
larginine (10 mM) or native low-density lipoprotein cholesterol (100 mg/dL) increased
endothelial O2
2 to the same degree. Asymmetric dimethylarginine also stimulated MCP-1
formation by endothelial cells. This effect was paralleled by activation of the redox-sensitive
transcription factor NF-kB. Preincubation of endothelial cells with ADMA increased the
adhesiveness of endothelial cells for THP-1 cells in a concentration-dependent manner.
Asymmetric dimethylarginine-induced monocyte binding was diminished by L-arginine or
by a neutralizing anti-MCP-1 antibody.
CONCLUSIONS We concluded that the endogenous NO synthase inhibitor ADMA is synthesized in human
endothelial cells. Asymmetric dimethylarginine increases endothelial oxidative stress and
potentiates monocyte binding. Asymmetric dimethylarginine may be an endogenous
proatherogenic molecule. (J Am Coll Cardiol 2000;36:2287–95) © 2000 by the American
College of Cardiology
Hypercholesterolemia reduces the biological activity of ni-
tric oxide (NO), impairs endothelium-dependent vasodila-
tion (1), increases platelet aggregation (2) and enhances
monocyte adhesion (3). The mechanism by which hyper-
cholesterolemia impairs the L-arginine/NO pathway is
probably multifactorial and dependent upon the stage of
atherosclerosis (4,5). Most studies have reported that the
defect is reversed by exogenous L-arginine (6–9). Recently,
asymmetric dimethylarginine (ADMA) has been character-
ized to be an endogenous, competitive inhibitor of NO
synthase (10). Asymmetric dimethylarginine has been
shown to be synthesized by human endothelial cells (11).
The plasma level of ADMA is elevated, and endothelial NO
elaboration is impaired in hypercholesterolemic rabbits as
well as in humans with atherosclerosis or with risk factors
for atherosclerosis (12–17).
Chronic supplementation with the NO precursor
L-arginine restores endothelial function and inhibits ath-
erosclerosis (18–22) and even induces regression (22).
Conversely, chronic inhibition of NO synthase promotes
monocyte adhesion and atherogenesis (23–26). Therefore, it
is possible that elevated ADMA levels in hypercholester-
olemic humans may promote atherosclerosis. Indeed, we
have recently reported that ADMA is a better predictor of
carotid artery intimal-medial thickness (as measured by
B-mode ultrasound) than the traditional risk factors (17).
An important mechanism by which NO may act as an
antiatherogenic molecule is by inhibiting endothelial adhe-
siveness for monocytes (27). Reduced NO elaboration has
been shown to be associated with increased oxidative stress
in endothelial cells (28), which, in turn, activates the
oxidant-responsive transcription factor NF-kB (29), leading
to enhanced endothelial adhesiveness associated with ex-
pression of adhesion molecules like vascular cell adhesion
molecule and monocyte chemotactic protein-1 (30–33).
In this study we determined that ADMA affects endo-
thelial cell-monocyte interactions in vitro, and we investi-
gated the mechanism leading to this effect.
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METHODS
Cell culture. The spontaneously transformed human um-
bilical vein endothelial cell line ECV 304 (ATCC, Rock-
ville, Maryland [34]) was cultured in medium M199 (Irvine
Scientific) containing 10% fetal calf serum, 100 U/mL
penicillin and 100 mg/mL streptomycin (Gibco BRL,
Grand Island, New York). This cell line retains many of the
characteristics of primary endothelial cells including the
synthesis of angiotensin-converting enzyme, NO and pros-
tacyclin and the expression of endothelial adhesion mole-
cules including intercellular adhesion molecule-1 and lym-
phocyte function associated antigen-3. The expression of
these adhesion molecules is upregulated by interleukin-1,
tumor necrosis factor-a and lipopolysaccharide stimulation
(35).
Human monocytoid cells (THP-1) (ATCC) were cul-
tured in RPMI medium 1640 (Irvine Scientific) supple-
mented with 10% fetal calf serum, 100 U/mL penicillin and
100 mg/mL streptomycin. The viability of THP-1 cells was
assessed before each experiment using trypan blue exclusion
and was always .95%.
Isolation of low-density lipoproteins (LDL). Human
plasma from two to three donors was obtained from the
Stanford blood bank, and butylated hydroxytoluene (BHT)
and EDTA were immediately added to the plasma to
achieve final concentrations of 20 mM and 0.1%, respec-
tively. Plasma was then mixed for 15 min at 4°C before
sequential gradient ultracentrifugation (1.019 to 1.063
g/mL adjusted with KBr) as described by Pritchard et al.
(36). The native LDL (nLDL) solution was then dialyzed
against 0.9% NaCl containing 20 mM BHT and 0.01%
EDTA overnight at 4°C. The cholesterol content of the
solution was measured by using a cholesterol oxidase color-
imetric kit (Sigma). The nLDL solution was stored at 4°C
and used for experiments within 2 weeks. For the prepara-
tion of oxidized LDL (oxLDL), nLDL solution was dia-
lyzed against 0.9% saline with 0.01% EDTA overnight to
eliminate the antioxidant BHT, and oxidation was induced
by adding 5 mM CuSO4 for 24 h at 4°C. Oxidation was
stopped by adding BHT (20 mM) before using the oxLDL
for the experiments.
Experimental conditions. Transformed human umbilical
vein endothelial cells were seeded onto 75 cm2 culture flasks
and maintained in M199 medium as described above. After
24 h the cells were washed twice with PBS, and fresh
medium was added. Cells were then maintained in culture
for 1, 2, 3, 5 or 7 days in the presence or absence of nLDL
(30, 100 and 300 mg/dL) or oxLDL (3 and 10 mg/dL)
before the cells and media were harvested for the measure-
ment of ADMA and symmetric dimethylarginine (SDMA)
levels. Endothelial integrity during incubation with nLDL
and oxLDL was assessed by measuring the activity of lactate
dehydrogenase in conditioned media using a commercially
available spectrophotometric assay kit (Sigma).
To assess the effects of dimethylarginines and lipopro-
teins on NO and monocyte chemotactic protein (MCP-1)
production and nuclear factor-kB activation, endothelial
cells were grown to confluence on six-well culture plates.
Cells were then washed twice with PBS, and fresh PBS
containing 0.7 mmol/L Ca21, 1.1 mmol/L Mg21, 2.7
mmol/L K1 and 6.1 mmol/L glucose was added. The cells
were then incubated for 4 h or 24 h in the presence or
absence of ADMA, SDMA or L, N-monomethylarginine
(L-NMMA) (each 0.1 to 100 mmol/L) or with ADMA in
the presence of 1mmol/L L-arginine. In other experiments
LDL (30, 100 or 300 mg/dL) or oxLDL (1 or 3 mg/dL) or
lipoproteins plus 1 mmol/L L-arginine were added to the
incubation medium. For the determination of endothelial
cell NO formation, the cells were stimulated with calcium
ionophore A23187 (1 mmol/L). After the end of the
incubation time, media were collected, and the cells were
gently detached with 5 mmol/L EDTA. Cells were counted
in a hemocytometer and subsequently lysed, and incubation
media and cell lysates were stored at 220°C until analysis.
Monocyte-endothelial cell adhesion assay. Transformed
human umbilical vein endothelial cells were grown to
confluence on six-well culture plates (Nunc, Naperville,
Illinois). Endothelial cells were incubated with the appro-
priate drugs or lipoproteins for 4 or 24 h before the adhesion
assays. Thirty minutes before the adhesion assay, endothe-
lial cells were washed with Hanks balanced salt solution
(HBSS) containing 2 mmol/L Ca21, 2 mmol/L Mg21 and
20 mmol/L HEPES (Irvine Scientific, San Francisco, Cal-
ifornia). Human monocytoid cells were washed with HBSS
and diluted to a final concentration of 2 3 106 cells/mL.
Human monocytoid cells (2 3 106) were added to each well
of endothelial cells. The THP-1 cells were allowed to
incubate with the endothelial monolayer at room tempera-
ture for 30 min on a rocking platform (Research Products
International, Mount Prospect, Illinois). Each well was
turned 90 degrees at 15 min to allow uniform distribution of
the THP-1 cells across the endothelial monolayer. Nonad-
herent mononuclear cells were carefully removed by two
Abbreviations and Acronyms
ADMA 5 asymmetric dimethylarginine
BHT 5 butylated hydroxytoluene
DDAH 5 dimethylarginine dimethylaminohydrolase
ECV 304 5 a line of transformed human umbilical vein
endothelial cells
ELISA 5 enzyme-linked immunosorbent assay
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HPLC 5 high-pressure liquid chromatography
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washes with HBSS and the adherent cells fixed with 2%
glutaraldehyde in HBSS. Adherent cells were counted by
microscopy using a computer-aided image analysis system
(ImageAnalyst, Automatix Corp., Billerica, Massachusetts).
Thirty fields were counted for each 35mm well, and the
mean number of adhering cells per field was calculated.
Determination of dimethylarginines. L-arginine,
ADMA and SDMA were quantified by high performance
liquid chromatography (HPLC) and precolumn derivatiza-
tion with o-phthaldialdehyde (OPA) using a modification
of a previously published method (13). Briefly, 10 mmol/L
L-homoarginine as internal standard was added to 1 mL of
cell supernatant or cell lysate. Samples and standards were
extracted on solid phase extraction cartridges (CBA Bond
Elut, Varian, Harbor City, California). The recovery rates
were 84 6 4%. The eluents were dried over nitrogen and
resuspended in bidistilled water for HPLC analysis. High
performance liquid chromatography was carried out on a
computer-controlled Varian Star chromatography system
(Varian, Walnut Creek, California) consisting of a ternary
gradient HPLC pump (Varian 9010), an automatic injector
with sample-reagent mixing capabilities (Varian 9050) and
a fluorescence detector (Varian Fluorichrom III). Samples
and standards were incubated for exactly 1 min with OPA
reagent (5.4 mg/mL OPA in borate buffer, pH 8.4, con-
taining 0.4% 2-mercaptoethanol) before automatic injection
into the HPLC. The OPA derivatives of L-arginine,
ADMA and SDMA were separated on a 250 3 4.5 mm
I.D. 7 mm Nucleosil phenyl column (Supelco, Bellefonte,
Pennsylvania) with the fluorescence detector set at lex 5
340 nm and lem 5 450 nm. Samples were eluted from the
column with 0.96% citric acid/methanol 70:30, pH 6.8, at a
flow rate of 1 mL/min. The variability of the method was
below 7%; the detection limit of the assay was 0.15 mmol/L.
Endothelial cell NO elaboration. The concentration of
nitrogen oxides (NOx) in supernatants from incubation
experiments of endothelial cells with dimethylarginines was
measured with a commercially available chemiluminescence
apparatus (model 2108, Dasibi) after reduction of the
samples in boiling acidic vanadium (III) at 98°C as previ-
ously described (22,23). Boiling acidic vanadium quantita-
tively reduces NO2
2 and NO3
2 to NO, which is quantified
by the chemiluminescence detector after reaction with
ozone. Signals from the detector were analyzed by a com-
puterized integrator and recorded as areas under the curve.
Standard curves for NOx were linear over the range of 50
pmol to 5 nmol/L (R2 5 0.997). The detection limit of this
assay was 65 pmol/L; intra- and interassay variability was
,6%.
Superoxide radical release by endothelial cells. For the
measurement of endothelial cell superoxide radical release,
cells were seeded into 12 mm scintillation counter vials
(Packard, Downers Grove, Illinois) and grown to conflu-
ence. After 24 h exposure to experimental agents, the cells
were washed with fresh PBS and incubated in PBS con-
taining 250 mmol/L of lucigenin. Photon emission was
recorded in a Packard Tricarb 1,500 liquid scintillation
analyzer in the single photon emission mode until equili-
bration was reached. The cells were then exposed to
phorbol-12-myristate-13-acetate (PMA, 2 mmol/L dis-
solved in dimethylsulfoxide), and photon emission was
recorded for 15 min. The specific chemiluminescence re-
sponse was expressed as counts per minute minus the
average background activity. After the end of the measure-
ments, the cells were gently detached with 5 mmol/L
EDTA, and cell protein was measured (37) according to the
Lowry method (32). Data were expressed as counts per
minute per nanograms of cell protein. This technique of
assessing superoxide anion elaboration is semiquantitative
but does provide an index of relative oxidative stress.
MCP-1 enzyme-linked immunosorbent assay. Monocyte
chemotactic protein-1 secretion by endothelial cells was
measured by ELISA with recombinant human MCP-1
(R&D Systems) as a standard. Briefly, 200 mL per well of
polyclonal goat-antihuman MCP-1 antibody (R&D Sys-
tems) in bicarbonate buffer (pH 9.6) at a final concentration
of 5 mg/mL was coated onto 96 well immunoplates over-
night. After washing with PBS containing EDTA and
Tween 20 (wash buffer), the plates were incubated with
blocking buffer (PBS containing 0.2% Triton X-100 and 1%
bovine serum albumin, pH 7.2) for 1 h at 37°C. Plates were
washed with wash buffer, and 200 mL of serially diluted
samples or standards was added. After incubation for 2 h
with shaking, the wells were rinsed with wash buffer.
Monoclonal mouse-antihuman MCP-1 antibody (200 mL
per well of 5 mg/mL) was then added and incubated for
90 min at 37°C. After washing the wells were incubated
with alkaline phosphatase-conjugated rabbit-antimouse
IgG monoclonal antibody (Sigma) for 90 min at 37°C.
Phosphatase substrate (Sigma; 1 mg/mL) was then added.
After 30 min of incubation at room temperature, the
products were measured at 405 nm by a microplate reader
(Biotek). The standard curve for MCP-1 measured by this
ELISA was linear from 0.3 to 50 ng/mL; the detection limit
was 1 ng/mL.
Electrophoretic mobility shift assay. Endothelial cells
were harvested, centrifuged to pellet cells and resuspended
in ice-cold PBS. Nuclear extracts were prepared according
to a modification of the procedure described by Dignam et
al. (32) as previously published. Cells were resuspended in
buffer A (in mmol/L: PMSF 0.5, HEPES 10 [pH 7.8],
MgCl2 1.5, KCl 10, DTT 0.5) containing 0.1% Nonidet
P-40 and disrupted in a tight fitting Dounce homogenizer.
Nuclei were then pelleted by centrifugation (25,000 g,
20 min, 4°C). Crude nuclei were resuspended in buffer C (in
mmol/L: HEPES 20 [pH 7.8], NaCl 0.42, MgCl2 1.5,
EDTA 0.2, DTT 0.5, PMSF 0.5; 25 vol% glycerol) and
incubated on ice for 30 min. The mixture was then spun at
25,000 g(20 min 4°C); the supernatant was collected, and
protein was quantified. Nuclear proteins were stored at
280°C until gel shift assay. Binding reactions were carried
out by mixing nuclear proteins with a double-stranded
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oligonucleotide corresponding with the published NF-kB-
binding domain. Reactions were performed with 32P-
labeled DNA oligonucleotide in the presence of (in
mmol/L) MgCl2 1, EDTA 0.5, DTT 0.5, NaCl 50,
Tris-HCl 10 (pH 7.5) and 0.05 mg/mL polydeoxyinosinic-
deoxycytidylic acid in 20 vol% glycerol. Samples were
separated on a 4% nondenaturating polyacrylamide gel and
exposed to x-ray film overnight.
Drugs. Asymmetric dimethylarginine and symmetric di-
methylarginine were purchased from Alexis (San Diego,
California). Unless noted, all other drugs were obtained
from Sigma (St. Louis, Missouri).
Calculations and statistical analysis. All data are given as
mean 6 SEM. Cell binding data are expressed as the mean
relative number of cells bound per high power field (cells/
hpf) from the analysis of 30 fields per culture well. Statistical
significance was tested in all experiments using analysis of
variance followed by Fisher protected least significant dif-
ference test. Statistical significance was assumed for p ,
0.05.
RESULTS
ADMA elaboration by endothelial cells. The concentra-
tions of ADMA and SDMA in ECV 304 human endothe-
lial cell incubation medium were 1.1 6 0.1 and 0.6 6 0.2
mmol/L, respectively, on day 1. They gradually increased to
3.0 6 0.5 and 1.9 6 0.3 mmol/L on day 7 (Fig. 1A). From
these data it was calculated that ECV 304 cells released
0.34 6 0.17 mmol ADMA/107 cells/24 h and 0.29 6 0.14
mmol SDMA/107 cells/24 h into the medium. L-arginine
concentrations in the medium were 120 to 160 mmol/107
cells without significant changes throughout the experimen-
tal period. The basal intracellular concentrations of
L-arginine, ADMA and SDMA were 426.5 6 51.5, 3.2 6
0.6 and 3.9 6 0.6 mmol/mg of cell protein, respectively.
Given a mean endothelial cell volume of approximately 1.02
pL (34), the intracellular concentrations of ADMA and
SDMA were calculated to be 7.9 6 1.3 mmol/L and 6.2 6
3.6 mmol/L at baseline and increased to 39.4 6 6.3 and
15.1 6 6.7 mmol/L on day 7. At any time point, the
intracellular DMA levels were 8 to 12-fold higher than the
concentrations in the conditioned medium.
Incubation with nLDL or oxLDL concentration depen-
dently increased ADMA release by endothelial cells (Fig.
1B). Transformed ECV 304 human umbilical vein endo-
thelial cells released 0.33 6 0.12, 0.44 6 0.06 and 0.52 6
0.10 m¨ol ADMA/107 cells/24 h into the medium in the
presence of nLDL (30, 100 and 300 mg/dL, respectively;
p , 0.05 vs. control for 100 and 300 mg/dL nLDL). In the
presence of oxLDL (3 and 10 mg/dL), ADMA release was
0.39 6 0.27 and 0.68 6 0.14 mmol ADMA/107 cells/24 h
(p , 0.05 vs. control for 10 mg/dL oxLDL). Lactate
dehydrogenase activity in conditioned media from endothe-
lial cells incubated with nLDL or oxLDL was not signifi-
cantly higher than from control cells (data not shown).
NO and superoxide elaboration by endothelial cells.
Incubation with ADMA or L-NMMA (0.1 to 100
mmol/L) concentration-dependently inhibited NO release
by ECV 304 cells (Fig. 2, Table 1). Coincubation with 1
mmol/L L-arginine reversed the inhibitory effect of ADMA
on NO formation.
Concomitantly with the inhibition of NO synthesis,
ADMA and L-NMMA increased endothelial superoxide
radical elaboration in a concentration-dependent manner
(Fig. 3, Table 1). The effect of ADMA on endothelial
Figure 1. (A) The synthesis of ADMA by the cultured human endothelial
cell line ECV 304. Data are mean 6 SEM for n 5 5 to 6 separate
experiments. The synthesis rates of ADMA and SDMA were calculated
from the mean differences in dimethylarginine concentrations between the
experimental days as 0.34 6 0.17 mmol ADMA/107 cells/24 h and 0.29 6
0.14 mmol SDMA/107 cells/24 h. (B) The effect of incubating endothelial
cells with nLDL or oxLDL on ADMA elaboration. Concentrations of
lipoproteins are given as mg/dL in legend. Data are mean of n 5 4 to 6
separate experiments. *p , 0.05 versus control. ADMA 5 asymmetric
dimethylarginine; nLDL 5 native low-density lipoprotein; oxLDL 5
oxidized low-density lipoprotein; SDMA 5 symmetric dimethylarginine.
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superoxide release was reversed by 1 mmol/L L-arginine.
Native low-density lipoprotein (100 mg/dL) stimulated
superoxide radical release by about two to three-fold, and
oxLDL (3 mg/dL) stimulated superoxide formation by
about 9 to 10-fold. Symmetric dimethylarginine had no
significant effect on endothelial NO or superoxide radical
release.
Monocyte adhesion. Asymmetric dimethylarginine and
L-NMMA increased the adhesiveness of ECV 304 human
endothelial cells for monocytoid cells in a concentration-
dependent manner (Fig. 4, Table 1). Symmetric dimethyl-
arginine had no significant effect on monocyte binding.
Incubation with nLDL (100 mg/dL) or oxLDL (3
mg/dL) increased monocyte binding by 60.4 6 12.4 and
117.2 6 16.6%, respectively (each p , 0.05 vs. control; Fig.
5). The stimulatory effects of ADMA or LDL on monocyte
binding were diminished by 1 mmol/L L-arginine or by a
neutralizing anti-MCP-1 antibody.
NF-kB activation. Incubation of ECV 304 endothelial
cells with ADMA, L-NMMA or with LDL lipoproteins
was associated with a concentration-dependent activation of
the transcription factor NF-kB (Fig. 6), while SDMA did
not activate NF-kB. The effects of ADMA, L-NMMA and
LDL on NF-kB activation were partly reversed by coincu-
bating the cells with excess L-arginine (1 mM) or with the
intracellular antioxidant pyrollidine dithiocarbamate
(PDTC, 1 mM).
MCP-1 secretion by endothelial cells. Asymmetric di-
methylarginine and L-NMMA concentration dependently
increased the release of MCP-1 from ECV 304 endothelial
cells. These stimulatory effects of the NO synthase inhibi-
tors were significantly diminished by L-arginine (Fig. 7,
Table 1); SDMA did not affect MCP-1 production by
endothelial cells. Incubation with nLDL or oxLDL also
stimulated MCP-1-release; the effect of LDL was dimin-
ished by L-arginine.
DISCUSSION
The salient findings of our study are that: 1) intracellular
ADMA levels are about 10-fold higher than the reported
range for plasma values; 2) inhibition of NO production by
ADMA increases endothelial superoxide radical elaboration
and NF-kB activation, resulting in enhanced MCP-1 ex-
pression and endothelial adhesiveness for monocytes, and 3)
these effects of ADMA are reversed by L-arginine.
Figure 2. The release of NOx from ECV 304 human endothelial cells
during 4 h of incubation in the presence or absence of ADMA, SDMA or
ADMA 1 L-arginine (1 mmol/L). Cells were stimulated with calcium
ionophore A23187 (1 mmol/L). Values are expressed as percent of the NOx
level in conditioned medium from control cells incubated with vehicle
alone. Data are mean 6 SEM of n 5 5 to 6 identical experiments.
ADMA 5 asymmetric dimethylarginine; NOx 5 nitrogen oxides;
SDMA 5 symmetric dimethylarginine.
Figure 3. The release of superoxide radicals from ECV 304 human
endothelial cells. Cells were incubated for 24 h with the substances
indicated before the addition of PMA (2 mmol/L). Data are mean 6 SEM
of n 5 3 to 4 experiments performed in duplicate. ADMA 5 asymmetric
dimethylarginine; nLDL 5 native low-density lipoprotein; oxLDL 5
oxidized low-density lipoprotein; SDMA 5 symmetric dimethylarginine.
Table 1. Plasma Lipid Profiles in Human Subjects
Normocholesterolemic Hypercholesterolemic
Total cholesterol (mg/dL) 185.3 6 7.2 262.0 6 6.1*
Low–density lipoprotein (mg/dL) 109.9 6 6.3 174.7 6 4.6*
High–density lipoprotein (mg/dL) 54.6 6 3.7 47.3 6 2.6
Triglyceride (mg/dL) 103.3 6 16.7 178.5 6 20.7†
*Significantly different from normocholesterolemic individuals (p , 0.0001); †significantly different from normocholesterolemic
individuals (p , 0.05).
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Vascular NO activity is decreased in hypercholesterol-
emia and atherosclerosis, leading to impaired endothelium-
dependent vasodilation (1), increased platelet aggregability
(38,39) and monocyte adhesiveness for the endothelium
(3,40). This impaired NO activity may contribute to the
development and progression of atherosclerosis. Indeed, in
animal models of hypercholesterolemia, pharmacological
inhibition of NO synthase promotes atherosclerosis (23–
26). On the other hand, enhancement of endogenous NO
formation with L-arginine supplementation improves en-
dothelial function (6–9,15), inhibits platelet activation and
monocyte adhesiveness for the endothelium (2,3,38–40)
and slows progression of lesions or even induces regression
(18–22,26). The benefit of L-arginine cannot be attributed
to reduced plasma levels of L-arginine in hypercholesterol-
emia (41,42) but are more likely due to its reversal of the
effects of ADMA, an inhibitor of the NOS pathway
(43,44).
ADMA metabolism. The pathways by which ADMA is
synthesized and degraded and the effect of hypercholester-
olemia on these pathways are under investigation. The
specific enzyme S-adenosylmethionine: protein arginine
N-methyltransferase (protein methylase I) has been shown
to methylate internal arginine residues in a variety of
polypepetides. Catabolism of these polypeptides generates
NG-monomethyl-L-arginine, NG, NG-dimethyl-L-
arginine and NG, NG9-dimethyl-L-arginine (45–47). The
metabolism of ADMA, but not SDMA, occurs via hydro-
lytic degradation to citrulline by the enzyme dimethylargi-
nine dimethylaminohydrolase (DDAH) (48). Inhibition of
DDAH causes a gradual vasoconstriction of vascular seg-
ments, which is reversed by L-arginine (46). This latter
finding suggests that inhibition of DDAH regulation could
reduce NO synthase activity. We have recently found that
exposure of vascular cells to oxidized lipoproteins in vitro
increases elaboration of ADMA into the conditioned me-
dium, which is temporally related to a decline in DDAH
activity (49). Moreover, in the hypercholesterolemic rabbit
(where plasma ADMA levels are elevated) DDAH activity
is reduced in the aorta, liver and kidney (49). Together,
these data and the current investigation suggest that ele-
vated ADMA levels may mediate some of the biological
effects of LDL on the endothelium in an autocrine or
paracrine manner.
Most importantly, within the concentration range we found
in cultured endothelial cells (5 to 40 mM), ADMA induced
pathophysiological changes of endothelial biology that also
occur in hypercholesterolemia. Inhibition of endothelial NO
synthase activity is associated with a concentration-dependent
increase of endothelial adhesiveness for human THP-1 mono-
cytoid cells. This effect of ADMA and L-NMMA mimics the
increase in adhesiveness observed when endothelial cells are
preincubated with nLDL; in both cases, adhesion is dimin-
ished by coincubating endothelial cells with L-arginine. Sup-
plementation of cholesterol-fed rabbits with L-arginine has
previously been shown to reduce aortic endothelial adhesive-
ness for monocytes (23).
NO and endothelial adhesiveness. Monocyte adhesion to
the endothelium is regulated via a variety of different cell
surface receptors on monocytes and endothelial cells (50). In
hypercholesterolemia and atherosclerosis, increased expres-
sion of vascular adhesion molecule-1 (51) and MCP-1 (52)
has been demonstrated. Upregulation of these proteins is
induced via increased intracellular oxidative stress, which
involves the induction of NF-kB-regulated transcriptional
pathways (30). The effects of oxidative stress on NF-kB
activation are counteracted by NO, resulting in downregu-
lation of the expression of vascular adhesion molecule-1(32)
Figure 4. The effect of preincubating ECV 304 human endothelial cells
with ADMA, SDMA or ADMA in the presence of 1 mmol/L L-arginine
on the adhesion of THP-1 human monocytoid cells. Endothelial cells were
coincubated with monocytoid cells for 30 min on a rocking platform.
Adhering cells were fixed in glutaraldehyde and counted using a computer-
aided image analysis system. Data are mean 6 SEM of three separate
experiments performed in triplicate. ADMA 5 asymmetric dimethylargi-
nine; SDMA 5 symmetric dimethylarginine.
Figure 5. Effect of coincubation with L-arginine (1 mmol/L) or with a
neutralizing anti-MCP-1 antibody on the effects of ADMA, nLDL (100
mg/dL) or oxLDL (3 mg/dL) on the adhesiveness of ECV 304 human
endothelial cells for THP-1 human monocytoid cells. ADMA 5 asym-
metric dimethylarginine; MCP-1 5 monocyte chemotactic protein;
nLDL 5 native low-density lipoprotein; oxLDL 5 oxidized low-density
lipoprotein. * 5 significantly different from vehicle treated control endo-
thelial cells, p , 0.05; † 5 significantly different from endothelial cells
treated with lipoprotein or ADMA.
2292 Bo¨ger et al. JACC Vol. 36, No. 7, 2000
ADMA: Effect on Endothelial Adhesiveness December 2000:2287–95
and MCP-1 (53). Nitric oxide also stabilizes the inhibitory
subunit I-kB, thereby blocking the activation of NF-kB and
its binding to specific domains on the DNA (54). There-
fore, one can assume that NO activity may regulate mono-
nuclear cell adhesiveness by affecting endothelial cell oxida-
tive stress. Indeed, we found that reduced endothelial NO
elaboration by ADMA or L-NMMA was associated with
increased superoxide radical-induced oxidative stress, as
measured by lucigenin chemiluminescence. L-arginine di-
minished superoxide anion release. Besides impaired
endothelium-dependent vasodilation and increased platelet
adhesion and aggregation, this autocrine antioxidant role of
NO may play a very important role in its antiatherogenic
effects.
Limitations and clinical implications. The current study
confirms previous observations of our group and others that
oxidized lipoprotein increases the endothelial release of
ADMA and that ADMA reduces the synthesis of NO
while increasing the generation of superoxide anion. How-
ever, in this study it took rather high concentrations
(10 mm) of exogenous ADMA to have a measurable effect
upon NO synthesis, superoxide anion generation and endo-
thelial adhesiveness. This concentration of ADMA is at the
upper range of plasma ADMA levels observed in disease (2
to 10 mm).
However, chronic exposure to the lower levels of ADMA
observed in disease states appears to have similar effects on
endothelial biology as does short-term exposure to the
higher dose used in this study. Specifically, we and others
have demonstrated that the two to three-fold increase in
plasma ADMA observed in hypercholesterolemic individu-
als is associated with reductions in endothelium dependent
vasodilation and urinary nitrate excretion—effects that are
reversed by administration of L-arginine (14,15). Moreover,
plasma ADMA levels in the subjects correlate better with
endothelial vasodilator function than does LDL cholesterol
(15).
The mechanism by which L-arginine exerts its beneficial
effects appears to be through enhanced production of
endothelium-derived NO (14,23). Originally, this was
termed the “arginine paradox,” because the effect of
L-arginine was surprising, given the low Km of the purified
endothelial NO synthase (2.9 mM) (41) and the relatively
high physiological plasma concentrations of L-arginine (60
to 100 mmol/L), which are unchanged in hypercholesterol-
emia (42).
The “L-arginine paradox” may be explained by the
presence of endogenous competitive NO inhibitors such as
ADMA (10). The ADMA plasma levels are approximately
1 mmol/L in healthy humans and are elevated two-fold in
hypercholesterolemic individuals ( 15). In elderly patients
with peripheral arterial disease and generalized atheroscle-
rosis, plasma ADMA levels range from 2.5 to 3.5 mmol/L,
corresponding to the severity of the vascular disease (14).
For patients with renal failure, plasma ADMA levels may be
elevated nine-fold (10).
Of note, we find that the intracellular ADMA level
within endothelial cells is considerably higher than those in
the conditioned media. The same may be true for ADMA
levels in endothelial cells in vivo with respect to human
Figure 6. The electrophoretic mobility shift assay showing the effect of
ADMA, SDMA and LDL lipoproteins on the activation of NF-kB.
Nuclear extracts were isolated from ECV 304 human endothelial cells after
incubation with the various substances for 24 h. Binding reactions were
carried out by mixing nuclear proteins with a 32P-labeled double-stranded
DNA oligonucleotide corresponding to the published NF-kB-binding
domain. In some experiments, unlabeled oligonucleotide corresponding to
the same NF-kB-binding domain (“competitor”) or to the SP-1 binding
domain (“noncomp”) was utilized. This experiment was replicated 3 times.
ADMA 5 asymmetric dimethylarginine; LDL 5 low-density lipoprotein;
MCP-1 5 monocyte chemotactic protein; nLDL 5 native low-density
lipoprotein; oxLDL 5 oxidized low-density lipoprotein; SDMA 5 sym-
metric dimethylarginine.
Figure 7. Release of monocyte chemotactic protein from ECV 304 human
endothelial cells during a 24 h incubation in the presence or absence of the
substances indicated. Data are mean 6 SEM of n 5 4 to 6 experiments
measured in duplicate. * 5 significantly different from vehicle treated
control endothelial cells, p , 0.05; † 5 significantly different from
endothelial cells treated with ADMA (1024 m) p , 0.05.
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plasma. Our observation that endothelial cells are a source
of ADMA corroborates the previous finding by Fickling et
al. (11). These elevations in plasma ADMA are likely of
pathophysiological significance because exogenous ADMA
concentrations between 1 and 10 mM affect the activity of
the NO synthase in rat mesentery tissue (43), in rat brain
(44) and in cultured macrophages (11). Faraci et al. (50)
calculated an IC50 (concentration inducing half-maximal
inhibition of enzyme activity) for ADMA of 1.8 mM in
cerebellar tissue (44), and Fickling et al. (11) reported that
2 and 10 mM ADMA inhibited nitrite production in
activated macrophages by 17 and 33%, respectively. These
data, taken together with the results of this study, suggest
that ADMA may be a potential autocrine regulator of
endothelial NO synthase.
In conclusion, our study shows that ADMA, an endog-
enous competitive inhibitor of NO synthesis, increases
endothelial superoxide radical formation, increases MCP-1
secretion and enhances adhesiveness of the endothelium for
monocytes. Asymmetric dimethylarginine elaboration in
endothelial cells is enhanced by LDL. Asymmetric di-
methylarginine may act as an autocrine proatherogenic
molecule in endothelial cells. Because ADMA is elevated in
many disorders associated with atherosclerosis (that is,
hypercholesterolemia, hypertension, diabetes mellitus, to-
bacco use, aging and hyperhomocysteinemia), it may repre-
sent one common pathway by which these risk factors
induce endothelial dysfunction and atherogenesis.
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